Month: June 2020
-
Fast Covid-19 Antibody Test Gets BARDA Funds
A company developing point-of-care diagnostics is receiving a federal government contract for a one-drop blood test that detects Covid-19 virus antibodies in five minutes.
-
Gene, Cell Therapy Start-Up Gains $700M in Early Funds
A biotechnology company creating engineered cells with modified genes for treating disease is raising $700 million in its first venture finance round.
-
Covid-19 Vaccine and Therapy Tracker Designed
A science graphics software company offers an online dashboard for tracking development of vaccines and therapies for Covid-19 infections.
-
Open-Source N95 Respirator Mask in the Works
An engineering partnership is designing a 3-D printed medical face mask needed by front-line health care workers, with its specifications soon to be made freely available.
-
Infographic – Steps to Control Covid-19 Transmission
The Lancet prepared a chart with the most effective measures for controlling person-to-person transmission, reproduced as this weekend’s infographic.
-
Convalescent Plasma Found Safe as Covid-19 Therapy
Donated blood plasma from people who recovered from Covid-19 infections is found to cause few serious side effects when given as a treatment for infections in others.
-
Gut Microbe Drug Shown to Prevent Return Infections
Early results from a clinical trial show an oral drug taken one time prevents more recurring infections from harmful gut bacteria than conventional treatments.
-
Program Reduces Long-Term Care Covid-19 Outbreaks
A collaborative program between an academic medical center and long-term care homes for older residents helps reduce Covid-19 infection outbreaks and deaths.
-
Non-Invasive Fetal Oxygen Monitor Designed
A university engineering lab created a device that safely monitors a fetus’s blood oxygen levels from outside the mother’s abdomen, which could reduce the rate of cesarean sections.
-
Covid-19 Dual Therapy Drug Trial Okayed
A company developing an oral drug that treats both Covid-19 infections and overactive immune system reactions received regulatory approval for a later-stage clinical trial.